Hyperemesis Gravidarum Clinical Trial
Official title:
The Effect of Mint Flavored Chewing Gum Application on Nausea Vomiting Severity, Coping With Stress and Anxiety Level in Pregnants With Hyperemesis Gravidarum
In the research planned as a randomized controlled study, the experimental groups will be administered routine hyperemesis gravidarum (HG) treatment as well as chewing mint-flavored gum, while the control group will only receive routine HG treatment and no intervention will be performed. This study aims to contribute to the literature by investigating the effect of chewing mint-flavored gum on the severity of nausea and vomiting, coping with stress, and anxiety levels due to hyperemesis gravidarum in pregnant women.
The data of the research will be collected after the necessary institutional permission and ethics committee approval have been obtained. Women who meet the inclusion criteria for the study will be informed about the method to be followed in the research. Those who want to participate in the research will read and sign the volunteer information form. 1. Intervention Group In data collection, pregnant women will sign an informed consent form before the application. Personal Information Form, VAS Scale, PUQE Scale, Stress Coping Styles Scale and State Anxiety Scale will be filled out. In addition to the routine treatment plan, the application will begin at least 4 hours after the antiemetic application (Gökbulut, 2021). The application will continue by chewing mint-flavored gum twice a day for at least 15 minutes for 3 days. The VAS scale will be filled after the morning chewing application, and the VAS Scale, PUQE Scale, Stress Coping Styles Scale and State Anxiety Scale will be filled in after the evening application. The forms of patients discharged during this period will be filled in via phone. 2. Control Group In data collection, pregnant women will sign an informed consent form before the application. At least 4 hours after the antiemetic application (Gökbulut, 2021), the Personal Information Form, VAS Scale, PUQE Scale and Stress Coping Styles Scale and State Anxiety Scale will be filled out. Routine treatment and nursing care will be applied to the control group, and no intervention will be performed. 1. After the forms are applied, the forms will continue to be filled for 3 days: VAS Scale in the morning, VAS Scale in the evening, PUQE Scale, Stress Coping Styles Scale and State Anxiety Scale. The forms of discharged patients will be filled in via phone. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04785911 -
Use of the Modified PUQE Score on Admitted Cases of Hyperemesis Gravidarum (HG) to Guide Response to Treatment
|
||
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Completed |
NCT04719286 -
MinSafeStart - Decision Aid Tool for Better Treatment of Nausea and Vomiting During Pregnancy
|
N/A | |
Completed |
NCT02300155 -
Improving Multivitamin Supplementation to Pregnant Women
|
Phase 4 | |
Completed |
NCT05175079 -
Acupressure in Hyperemesis Gravidarum
|
N/A | |
Completed |
NCT05098067 -
Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy
|
Phase 2 | |
Completed |
NCT01836835 -
Pregnancy Specific Nausea Questionnaire (PUQE) Translated and Tested in Norwegian
|
N/A | |
Completed |
NCT03950167 -
Gallbladder Functions & Serum Cholecystokinin Levels in Women Diagnosed With Hyperemesis Gravidarum
|
||
Completed |
NCT02830321 -
The Association of Helicobacter Pylori in the Pathogenesis of Hyperemesis Gravidarum in Pregnant Women
|
N/A | |
Completed |
NCT02541682 -
Assessment of the Relationship Between Affective Temperament and the Severity of Nausea and Vomiting in Early Pregnancy
|
N/A | |
Terminated |
NCT03785691 -
Validating the Effect og Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum
|
Phase 2 | |
Completed |
NCT05446025 -
The Levels of the Orexin, Galanin and aMSH and CART in Patients With Hyperemesis Gravidarum
|
||
Recruiting |
NCT02862496 -
Bone Health in Hyperemesis Gravidarum
|
N/A | |
Completed |
NCT02163434 -
Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum
|
Phase 2 | |
Terminated |
NCT05452174 -
Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06442813 -
Effects Of Emotional Freedom Technique and Hypermesis Gravidarum
|
N/A | |
Completed |
NCT06245811 -
Inflammation Markers in Hyperemesis Gravidarum
|
||
Completed |
NCT04828967 -
Use of Hypnosis in Hyperemesis Gravidarum
|
N/A | |
Completed |
NCT03127293 -
Hyperemesis Gravidarum and Osteoporosis
|
N/A | |
Completed |
NCT01559012 -
Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum
|
Phase 3 |